Treatment-related adverse events
| N=57 (%) | ||
| Treatment-related adverse events | ||
| All grade | 49 (86.0) | |
| Grade 3–5 | 17 (29.8) | |
| That led to discontinuation | 7 (12.3) | |
| Grade 3–5 | All grade | |
| Aspartate aminotransferase increase | 5 (8.8) | 6 (10.5) |
| Alanine aminotransferase increase | 4 (7.0) | 7 (12.3) |
| Lipase increase | 4 (7.0) | 6 (10.5) |
| Fatigue | 2 (3.5) | 26 (45.6) |
| Diarrhea | 2 (3.5) | 20 (35.1) |
| Anemia | 1 (1.8) | 11 (19.3) |
| Mucositis | 1 (1.8) | 6 (10.5) |
| Anorexia | 1 (1.8) | 4 (7.0) |
| Fever | 1 (1.8) | 3 (5.3) |
| Thrombopenia | 1 (1.8) | 3 (5.3) |
| Acute kidney injury | 1 (1.8) | 1 (1.8) |
| Diabetes | 1 (1.8) | 0 (0.0) |
| Gastritis | 1 (1.8) | 0 (0.0) |
| Pulmonary sarcoidosis | 1 (1.8) | 0 (0.0) |
| Creatine phosphokinase increase | 1 (1.8) | 0 (0.0) |
| Adrenal insufficiency | 1 (1.8) | 3 (5.3) |
| Hyperthyroidism | 0 (0.0) | 8 (14.0) |
| Hypothyroidism | 0 (0.0) | 6 (10.5) |